Myeloid Leukemia
This is an emerging topic with the recent recruitment of Melania Tesio (CRCN, INSERM) who has a long experience in this field. Acute myeloid leukemia (AML) is a heterogeneous malignancy characterized by the clonal proliferation of immature myeloid progenitors. Despite significant progress in the characterization of AML molecular and genetic basis, AML remains a clinically challenging disease with a poor prognosis (35% overall survival at 5-years). This calls for new therapeutic alternatives to improve AML treatment. In our group, we combine in vitro cell lines, primary AML cells and in vivo murine and xenograft models AML to identify novel therapeutic targets in AML. This project is supported by the Fondation ARC pour la recherche sur le cancer.